(IGC) India Globalization Capital - Ratings and Ratios

IGC Pharma, Inc. operates as a clinical-stage pharmaceutical company focused on developing innovative treatments for neurodegenerative disorders, particularly Alzheimers disease. The companys lead candidate, IGC-AD1, is currently in a Phase 2B clinical trial targeting agitation in dementia associated with Alzheimers. This condition represents a significant unmet medical need, with agitation affecting approximately 70% of Alzheimers patients. IGC-AD1s unique mechanism of action targets the GABAergic system, offering potential advantages over existing treatments. The company also has a pipeline of pre-clinical compounds, including TGR-63, IGC-1C, IGC-M3, and LMP, which are under development for various neurological conditions.

Formerly known as India Globalization Capital, Inc., the company rebranded as IGC Pharma, Inc. in March 2023 to reflect its strategic shift toward pharmaceutical development. Incorporated in 2005, IGC Pharma is headquartered in Potomac, Maryland, and has transitioned from its prior focus on infrastructure and materials to a specialized biopharmaceutical approach. This shift underscores the companys commitment to addressing critical gaps in neurodegenerative disease treatments.

Ticker Symbol: IGC Exchange: NYSE MKT Type: common stock Country Origin: United States GICS Sub Industry: Trading Companies & Distributors Average Volume 20d: 357140 Last Price: 0.31 SMA 20: 0.30 SMA 50: 0.32 SMA 200: 0.38 ATR: 0.02 Market Cap: 23.11M USD P/E: 0.00 P/E Forward: 0.00 P/B: 3.59 P/S: 18.70 RoE: None 3-Month Forecast: Based on the provided and , IGCs stock is expected to remain under pressure due to its low price range (SMA 20: 0.30, SMA 50: 0.32) and high volatility (ATR: 0.02). The companys market cap of $23.11M and P/S ratio of 18.70 suggest limited upside potential in the near term. However, the low P/S ratio could indicate undervaluation, depending on the markets perception of the companys pipeline progress.